166 related articles for article (PubMed ID: 25238640)
21. In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.
Marsden MD; Loy BA; Wu X; Ramirez CM; Schrier AJ; Murray D; Shimizu A; Ryckbosch SM; Near KE; Chun TW; Wender PA; Zack JA
PLoS Pathog; 2017 Sep; 13(9):e1006575. PubMed ID: 28934369
[TBL] [Abstract][Full Text] [Related]
22. The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.
Ruan BF; Zhu HL
Curr Med Chem; 2012; 19(16):2652-64. PubMed ID: 22506770
[TBL] [Abstract][Full Text] [Related]
23. Total synthesis of bryostatin 9.
Wender PA; Schrier AJ
J Am Chem Soc; 2011 Jun; 133(24):9228-31. PubMed ID: 21618969
[TBL] [Abstract][Full Text] [Related]
24. Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.
Kedei N; Telek A; Michalowski AM; Kraft MB; Li W; Poudel YB; Rudra A; Petersen ME; Keck GE; Blumberg PM
Biochem Pharmacol; 2013 Feb; 85(3):313-24. PubMed ID: 23146662
[TBL] [Abstract][Full Text] [Related]
25. Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes.
Ryckbosch SM; Wender PA; Pande VS
Nat Commun; 2017 Feb; 8(1):6. PubMed ID: 28232750
[TBL] [Abstract][Full Text] [Related]
26. Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death.
Staveness D; Abdelnabi R; Schrier AJ; Loy BA; Verma VA; DeChristopher BA; Near KE; Neyts J; Delang L; Leyssen P; Wender PA
J Nat Prod; 2016 Apr; 79(4):675-9. PubMed ID: 26900625
[TBL] [Abstract][Full Text] [Related]
27. Structural insights into the interactions of phorbol ester and bryostatin complexed with protein kinase C: a comparative molecular dynamics simulation study.
Thangsunan P; Tateing S; Hannongbua S; Suree N
J Biomol Struct Dyn; 2016 Jul; 34(7):1561-75. PubMed ID: 26292580
[TBL] [Abstract][Full Text] [Related]
28. A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts.
Khan TK; Nelson TJ; Verma VA; Wender PA; Alkon DL
Neurobiol Dis; 2009 May; 34(2):332-9. PubMed ID: 19233276
[TBL] [Abstract][Full Text] [Related]
29. Identification of a tunable site in bryostatin analogs: C20 Bryologs through late stage diversification.
Wender PA; Baryza JL
Org Lett; 2005 Mar; 7(6):1177-80. PubMed ID: 15760168
[TBL] [Abstract][Full Text] [Related]
30. Deletion of the C26 Methyl Substituent from the Bryostatin Analogue Merle 23 Has Negligible Impact on Its Biological Profile and Potency.
Zhao X; Kedei N; Michalowski A; Lewin NE; Keck GE; Blumberg PM
Chembiochem; 2018 May; 19(10):1049-1059. PubMed ID: 29517836
[TBL] [Abstract][Full Text] [Related]
31. Designed PKC-targeting bryostatin analogs modulate innate immunity and neuroinflammation.
Abramson E; Hardman C; Shimizu AJ; Hwang S; Hester LD; Snyder SH; Wender PA; Kim PM; Kornberg MD
Cell Chem Biol; 2021 Apr; 28(4):537-545.e4. PubMed ID: 33472023
[TBL] [Abstract][Full Text] [Related]
32. Biological activity of the bryostatin analog Merle 23 on mouse epidermal cells and mouse skin.
Kelsey JS; Cataisson C; Chen J; Herrmann MA; Petersen ME; Baumann DO; McGowan KM; Yuspa SH; Keck GE; Blumberg PM
Mol Carcinog; 2016 Dec; 55(12):2183-2195. PubMed ID: 26859836
[TBL] [Abstract][Full Text] [Related]
33. Substitution on the A-ring confers to bryopyran analogues the unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters.
Keck GE; Poudel YB; Welch DS; Kraft MB; Truong AP; Stephens JC; Kedei N; Lewin NE; Blumberg PM
Org Lett; 2009 Feb; 11(3):593-6. PubMed ID: 19113896
[TBL] [Abstract][Full Text] [Related]
34. Role of the C8 gem-dimethyl group of bryostatin 1 on its unique pattern of biological activity.
Keck GE; Poudel YB; Rudra A; Stephens JC; Kedei N; Lewin NE; Blumberg PM
Bioorg Med Chem Lett; 2012 Jun; 22(12):4084-8. PubMed ID: 22579485
[TBL] [Abstract][Full Text] [Related]
35. Total synthesis of bryostatin 3.
Trost BM; Wang Y; Buckl AK; Huang Z; Nguyen MH; Kuzmina O
Science; 2020 May; 368(6494):1007-1011. PubMed ID: 32467391
[TBL] [Abstract][Full Text] [Related]
36. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
Marsden MD; Wu X; Navab SM; Loy BA; Schrier AJ; DeChristopher BA; Shimizu AJ; Hardman CT; Ho S; Ramirez CM; Wender PA; Zack JA
Virology; 2018 Jul; 520():83-93. PubMed ID: 29800728
[TBL] [Abstract][Full Text] [Related]
37. Function-Oriented Synthesis: Design, Synthesis, and Evaluation of Highly Simplified Bryostatin Analogues.
Wender PA; Sloane JL; Luu-Nguyen QH; Ogawa Y; Shimizu AJ; Ryckbosch SM; Tyler JH; Hardman C
J Org Chem; 2020 Dec; 85(23):15116-15128. PubMed ID: 33200928
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of seco-B-ring bryostatin analogue WN-1 via C-C bond-forming hydrogenation: critical contribution of the B-ring in determining bryostatin-like and phorbol 12-myristate 13-acetate-like properties.
Andrews IP; Ketcham JM; Blumberg PM; Kedei N; Lewin NE; Peach ML; Krische MJ
J Am Chem Soc; 2014 Sep; 136(38):13209-16. PubMed ID: 25207655
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Chromane-Based Bryostatin Analogues Prepared via Hydrogen-Mediated C-C Bond Formation: Potency Does Not Confer Bryostatin-like Biology.
Ketcham JM; Volchkov I; Chen TY; Blumberg PM; Kedei N; Lewin NE; Krische MJ
J Am Chem Soc; 2016 Oct; 138(40):13415-13423. PubMed ID: 27676096
[TBL] [Abstract][Full Text] [Related]
40. Total synthesis of bryostatin 16 using a Pd-catalyzed diyne coupling as macrocyclization method and synthesis of C20-epi-bryostatin 7 as a potent anticancer agent.
Trost BM; Dong G
J Am Chem Soc; 2010 Nov; 132(46):16403-16. PubMed ID: 21043491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
